The Comparison of Newly Diagnosed Invasive Breast Patient Cohorts in Genomics Evidence Neoplasia Information Exchange Biopharma Collaborative (GENIE-BPC) and Other Real-World Databases.

Autor: Liu X; Epidemiology, Biostatistics and Research Decision Sciences, Merck & Co., Inc., West Point, Pennsylvania, USA., Alipour GH; Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA., Shao C; Epidemiology, Biostatistics and Research Decision Sciences, Merck & Co., Inc., West Point, Pennsylvania, USA., Burcu M; Epidemiology, Biostatistics and Research Decision Sciences, Merck & Co., Inc., West Point, Pennsylvania, USA., Bortnichak E; Epidemiology, Biostatistics and Research Decision Sciences, Merck & Co., Inc., West Point, Pennsylvania, USA., Vo T; Epidemiology, Biostatistics and Research Decision Sciences, Merck & Co., Inc., West Point, Pennsylvania, USA., Yu CL; Epidemiology, Biostatistics and Research Decision Sciences, Merck & Co., Inc., West Point, Pennsylvania, USA.
Jazyk: angličtina
Zdroj: Pharmacoepidemiology and drug safety [Pharmacoepidemiol Drug Saf] 2024 Aug; Vol. 33 (8), pp. e5851.
DOI: 10.1002/pds.5851
Abstrakt: Background: Oncology databases that integrate genomic and clinical data have become valuable resources for precision medicine. However, the generalizability of these databases has not been comprehensively assessed.
Objectives: To describe the demographics, clinical characteristics, treatments, and overall survival of breast cancer cohorts in GENIE-BPC and three other databases.
Methods: This study utilized GENIE-BPC, SEER, SEER-Medicare, and Merative MarketScan Research Databases. Women with invasive breast cancer were identified through EHR, cancer registries or ICD-9/10-CM codes. The ages were 18+ years or per database requirement. Treatments were based on EHR or HCPCS/NDC codes in claims. Overall survival was estimated as time from diagnosis to death.
Results: Of female breast cancer patients in GENIE-BPC (n = 775), SEER (n = 548 336), SEER-Medicare (n = 68 914), and Marketscan (n = 109 499) databases, the median ages at initial diagnosis were 44, 62, 74, and 57 years, respectively. A greater proportion of patients in GENIE-BPC, compared to SEER/SEER-Medicare, had higher nuclear grades (%III-%IV: 57% vs. 26%/24%), advanced disease stage (%IV: 25.3% vs. 5%/3.6%), percent of triple negative breast cancer (19.7% vs. 10.2%/8.5%), and receipt of chemotherapy (85.0% vs. NA/22.3%). The 1-, 3-, and 5-year overall survival rates were lower in GENIE-BPC (78.5%, 60.5%, 55.5%) than in SEER (95.8%, 89.5%, 85.5%) and SEER-Medicare (91.6%, 81.4%, 75.0%).
Conclusion: Breast cancer patients in GENIE-BPC were younger, had more advanced disease, had a higher proportion of triple negative breast cancer and recipients of chemotherapy, and had poorer overall survival. Researchers must use statistical adjustment when extrapolating results (e.g., biomarker prevalence) from GENIE-BPC to the larger breast cancer population.
(© 2024 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: